Thermo Fisher Stocks Rise as JPMorgan Adds October Favorite
Thermo Fisher Scientific (TMO) shares rose by approximately 1.1% to $662.27 after JPMorgan added the company to its October growth selections. The company's second-quarter results showed strong performance with revenue climbing 10% and operating income increasing 14%, indicating improved profitability. While the valuation is high, sustained organic growth and further margin gains are crucial for continued investor confidence, especially with new AI-driven Orbitrap platforms needing to translate into customer spending.
JPMorgan’s October Picks Hint at 3 ETF Trades: Value, AI Power and Healthcare - State Street Financial Se
JPMorgan's latest stock picks for October suggest a diversified investment strategy beyond just AI, focusing on value, AI-related power infrastructure, and healthcare sectors. The bank added American Express (AXP), Liberty Energy (LBRT), and Thermo Fisher Scientific (TMO) to its favorites, all with overweight ratings. ETFs are presented as a way for investors to gain exposure to these themes without single-stock risk, highlighting funds like Vanguard Financials ETF (VFH), VanEck Oil Services ETF (OIH), and Health Care Select Sector SPDR Fund (XLV).
Here’s How Much You Would Have Made Owning Thermo Fisher Scientific Stock In The Last 10 Years
Thermo Fisher Scientific (NYSE: TMO) has outperformed the market over the past decade, achieving an average annual return of 15.7%. An initial investment of $100 in TMO stock 10 years ago would now be worth $418.67, highlighting the significant impact of compounded returns. The company currently holds a market capitalization of $247.03 billion.
Thermo Fisher Scientific stock after-hours at EUR 593.80: plus 2.03 percent versus prior close
Thermo Fisher Scientific stock rose 2.03 percent in after-hours trading on October 5, 2026, reaching EUR 593.80. This increase follows a September 15 announcement of a partnership with Mayo Clinic to launch Precure, LLC. The new venture, majority-owned by Mayo Clinic with Thermo Fisher as a minority owner, aims to integrate various clinical data using Thermo Fisher's advanced proteomics and mass spectrometry platforms.
Thermo Fisher Scientific stock carries raised 2026 guidance
Thermo Fisher Scientific (NYSE: TMO) has raised its 2026 guidance following a strong second quarter, with revenue up 10% and adjusted EPS up 13%. The company's stock was trading at USD 654.80 on October 2, 2026, marking a 13% year-to-date increase. JPMorgan has added Thermo Fisher to its October favorite stock ideas with an overweight rating, citing the company's financial outlook, AI adoption, and US biopharma reshoring.
RBC Raises Price Target on Danaher to $250 From $215, Keeps Outperform Rating
RBC has increased its price target for Danaher Corporation (DHR) to $250 from $215, while maintaining an Outperform rating on the stock. This adjustment reflects RBC's continued positive outlook on the company. The article also notes recent executive changes at Danaher and other analyst price target updates.
Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus
Zacks Investment Research highlights several stocks that have outperformed the market, demonstrating the effectiveness of their analytical methodologies. The article details the performance of stocks upgraded through Zacks Rank, Zacks Recommendation, and those featured in their Focus List, ECAP, ECDP, and Top 10 Stocks portfolios, including Biodesix, Fastly, Cricut, Precigen, Palantir, Shopify, Thermo Fisher, Intercontinental Exchange, Quest Diagnostics, Fastenal, and Monolithic Power Systems. It emphasizes Zacks' track record in providing investors with guidance to beat market benchmarks.
Thermo Fisher Scientific accelerates market access by prioritizing the right KOLs
Thermo Fisher Scientific has significantly improved its market access strategy by implementing Veeva Link Key People, a platform that centralizes and dynamically tracks Key Opinion Leader (KOL) data. This shift from fragmented, manual data systems has allowed them to identify new researchers, personalize engagement, achieve a high ROI, and save labor. The platform provides comprehensive KOL insights, standardizes prioritization, and translates real-time intelligence into actionable strategies, thereby proving market demand and uncovering hidden opportunities.
Thermo Fisher Scientific stock heads into October 21 results
Thermo Fisher Scientific (TMO) is set to release its Q3 2026 earnings on October 21, 2026, after closing at USD 654.80 on October 2. The upcoming report follows a strong Q2 performance where revenue rose 10.5% to USD 11.99 billion and adjusted earnings beat estimates. Analysts have a "Moderate Buy" consensus but with a wide target range, and the stock remains below its 52-week high, making the Q3 results a crucial test for its valuation.
Thermo Fisher Scientific Inc. (TMO) options chain
This article provides the options chain for Thermo Fisher Scientific Inc. (TMO) for the expiry date of November 20, 2026. It lists detailed data for both Call and Put options, including strike price, last trade price, bid, ask, change, volume, open interest, and implied volatility. The data is delayed by 15 minutes and the stock price for TMO is shown as $654.80 at the close of October 2nd.
Thermo Fisher Scientific announces results call: what it means for Thermo Fisher Scientific stock
Thermo Fisher Scientific (US8835561023) announced it will release its third-quarter 2026 results before the market opens on October 21, with an earnings conference call on the same day. The stock traded at EUR 582.00 in weekend trading on October 3, 2026, a slight increase from its previous close. The company also recently introduced the Gibco CHO-K1 Catalog Panel, a new cGMP-ready media portfolio showing significant improvements in cell density and titer in studies.
Mayo Clinic and Thermo Fisher Scientific launch Precure LLC to identify signs of disease before their symptoms appear
Mayo Clinic and Thermo Fisher Scientific have launched Precure LLC, a joint venture aimed at understanding biological changes that occur before disease symptoms appear. This initiative will create a large biomedical dataset by integrating proteomic, genomic, and longitudinal clinical data from one million biospecimens. The goal is to accelerate drug development, enable earlier diagnoses, and lead to more personalized treatments for a wide range of diseases.
Thermo Fisher Scientific launches Gibco CHO-K1 Catalog Panel
Thermo Fisher Scientific has launched the Gibco CHO-K1 Catalog Panel, a cGMP-ready portfolio of basal and feed media for optimizing cell growth and protein production in CHO-K1 cell lines. The panel offers flexible liquid and dry powder formats and helps development teams quickly identify high-performing media and feed combinations. Studies show that select combinations can lead to significantly higher titer and peak viable cell density compared to benchmark products, supporting scalable biologics manufacturing.
Cogent Biosciences Inc (COGT-Q) Stock Price and News
This article provides stock price and news for Cogent Biosciences Inc. (COGT-Q), including recent analyst ratings, announcements of new drug application submissions, and detailed clinical data presentations. The company, focused on developing precision therapies, has seen significant news regarding its drug bezuclastinib for advanced systemic mastocytosis and gastrointestinal stromal tumors.
Thermo Fisher Scientific Inc (TMO) Shares Fall 3.3% -- What GF S
Thermo Fisher Scientific Inc (TMO) shares dropped 3.3% to $652.51, currently trading 8.5% above its GF Value™ estimate of $601.20, indicating it is overvalued. Despite a strong GF Score™ of 85/100, insider selling of $158.1 million with no buying activity raises concerns, suggesting caution for potential investors. The stock's current P/E ratio of 35.1x is also higher than its historical median, further supporting the overvaluation assessment.
Danaher Corp Stock (DHR) Moved Down by 3.29% on Oct 1: What Investors Need To Know
Danaher Corp (DHR) stock declined by 3.29% on October 1st due to profit-taking in high-valuation life sciences and healthcare stocks, as well as investor caution ahead of its third-quarter earnings release. Despite strong fundamentals and technical buy signals from MACD, short-term price action will remain sensitive to macroeconomic sentiment and order visibility. The article also highlights company-specific risks including executive leadership transition, bioprocessing revenue deferrals, elevated valuation, and M&A balance sheet leverage with China headwinds.
Thermo Fisher schedules results as Thermo Fisher Scientific stock costs EUR 592.70
Thermo Fisher Scientific (TMO) will release its Q3 2026 results before market open on October 21, 2026. The company recently reported a 10% increase in Q2 revenue to USD 11.99 billion and raised its full-year 2026 guidance. Analysts have a wide valuation range for the stock, with an average target of USD 628.78.
Gilead Sciences, Inc. (GILD) stock price, news, quote and history
This article provides a comprehensive overview of Gilead Sciences, Inc. (GILD) stock, including its current price, recent news headlines, and performance data. It highlights the stock's trading activity, various news articles discussing its trends and comparisons with other healthcare stocks, and its trailing total returns against the S&P 500. The data indicates strong performance for GILD across different timeframes.
Thermo Fisher Scientific stock pre-market at EUR 598.30: plus 0.28 percent
Thermo Fisher Scientific stock rose 0.28 percent to EUR 598.30 in pre-market trading, compared to its previous close of EUR 596.60. The company also announced that it will release its third-quarter 2026 financial results on October 21, 2026, before the market opens.
Should CHO K1 Media Launch Require Action From Thermo Fisher Scientific Stock Investors?
Thermo Fisher Scientific recently launched the Gibco CHO-K1 Catalog Panel, a cGMP-ready media suite aimed at supporting CHO-K1 cell growth and protein production for biologics and biosimilars developers. This new product is expected to support Thermo Fisher Scientific's recurring consumables business, helping to offset potential macro headwinds in the instrument market. While the launch is a positive step, its impact on the company's investment narrative depends on execution and adoption rates in the bioprocessing sector.
Thermo Fisher Scientific stock raises guidance and trades at EUR 596.90
Thermo Fisher Scientific (TMO) has raised its 2026 revenue guidance to between $47.4 billion and $48.1 billion, with adjusted EPS guidance of $24.93 to $25.33, following a strong Q2 2026 performance. The company reported a 10% year-over-year revenue increase to $11.99 billion and a 13% rise in adjusted EPS to $6.03 for Q2. Goldman Sachs has also increased its price target for TMO to $780.00, maintaining a Buy rating.
Thermo Fisher (TMO) credits director pay as stock units at $675 each.
Jennifer M. Johnson, a director at Thermo Fisher Scientific Inc. (TMO), acquired 46.3 Phantom Stock Units valued at $675.00 each on September 26, 2026, under the company's Deferred Compensation Plan for Directors. This transaction increased her total holdings to 768.52 units, which are convertible into Common Stock on a 1-for-1 basis upon cessation of director service or a change of control. The units represent deferred quarterly retainers based on the stock's closing price at quarter-end.
Thermo Fisher Scientific Inc (TMO) Stock Up 0.1% but GF Value Says Overvalued -- GF Score: 85/100
Thermo Fisher Scientific Inc (TMO) saw its stock rise 0.1% to $679.61, but GuruFocus's GF Value suggests it is overvalued by 13.1% compared to its estimated fair value of $600.92. Despite a strong GF Score of 85/100, indicating solid fundamentals in profitability and momentum, the valuation and recent insider selling activity raise concerns for potential investors, suggesting a cautious approach and waiting for a more attractive entry point.
Thermo Fisher Director Credited 55.56 Stock Units
Thermo Fisher Scientific Inc. director Dion J. Weisler was credited with 55.56 Phantom Stock Units on September 26, 2026, under the company's Deferred Compensation Plan for Directors. These units, valued at $675.00 each, are convertible to common stock on a 1-for-1 basis and are distributable upon cessation of director service or a change of control. Following this transaction, Weisler's direct holdings in Phantom Stock Units totaled 2,846.55.
At $675 per unit, a Thermo Fisher (TMO) director was credited with 62.96 stock units.
Thermo Fisher Scientific Inc. director Scott M. Sperling was credited with 62.96 Phantom Stock Units on September 26, 2026, at a price of $675.00 per unit under the company's Deferred Compensation Plan for Directors. These units are convertible to common stock on a 1-for-1 basis and become distributable upon the cessation of director service or a change of control. Following this transaction, Sperling's reported balance increased to 17,737.6000 units.
Thermo Fisher Scientific (NYSE:TMO) Stock: Faster Organic Growth Lifts Its 2026 Outlook
Thermo Fisher Scientific (NYSE:TMO) has increased its 2026 outlook following strong second-quarter results, which showcased accelerated organic growth, improved adjusted margins, and early contributions from recent acquisitions. The company reported a 10% rise in revenue to $11.99 billion and a 13% increase in adjusted earnings per share. Concurrently, Thermo Fisher is strategically reshaping its portfolio by acquiring Clario and divesting its microbiology unit.
Arm Holdings plc (ARM) Stock forecasts
This article provides an analyst report on Arm Holdings plc (ARM) from Morningstar, dated September 28, 2026. It highlights that Arm, as the dominant IP owner for smartphone CPU cores and other battery-powered devices, is experiencing accelerating CPU demand. The report emphasizes the critical need for Arm to secure sufficient supply to capitalize on this growing demand.
Thermo Fisher Scientific stock trades at EUR 596.90 before October 21 results
Thermo Fisher Scientific stock was trading at EUR 596.90, up 0.49 percent, on September 29, 2026, ahead of its Q3 2026 earnings report scheduled for October 21, 2026. The company previously beat Q2 2026 EPS and revenue estimates, and analysts have a "Moderate Buy" consensus despite varied price targets. Thermo Fisher is maintaining its fiscal 2026 EPS guidance.
Thermo Fisher Scientific (TMO) Adds New Separation Platform To Its Proteomics Toolkit
Thermo Fisher Scientific has expanded its proteomics offerings by signing a reseller agreement to integrate Evosep's Eno separation platform into its mass spectrometry lineup. This move enhances Thermo Fisher's "end-to-end" toolkit strategy, aiming for deeper integration into biopharma workflows and increased customer stickiness. While this strengthens its market position, it also introduces potential margin pressures associated with third-party platform reliance and revenue-sharing terms.
Yokogawa Brings Publication-Backed Validation from More Than 60,000 Scientific Publications to its CSU Spinning Disk Confocal Systems with Bioz
Bioz, Inc. is collaborating with Yokogawa Life Sciences to integrate publication-backed validation for Yokogawa's CSU spinning disk confocal systems. This partnership uses Bioz Badges to transform Yokogawa's extensive publication history (over 60,000 scientific publications) into an accessible resource for researchers, making scientific evidence directly available on Yokogawa's website. The system also supports Yokogawa's internal teams by providing an efficient way to access and utilize product-specific literature for various initiatives.
Thermo Fisher Scientific (TMO) Stock Seems Reasonable Following Its 47% Run
Thermo Fisher Scientific's stock has seen a significant 47.4% return over the past year, prompting an evaluation of its current valuation against projected cash flows. A Discounted Cash Flow (DCF) model suggests the stock's intrinsic value is largely in line with its current price of $678.60, supported by expected growth in free cash flow and strategic collaborations. While the community has divided narratives—some seeing it as 7% undervalued due to demographic shifts and gene therapy demand, others viewing it as 5% overvalued due to reliance on cost management—the overall sentiment points to a reasonable valuation.
Weekly Recap: HC Wainwright $38 target and advances two ctDNA MRD programs
HC Wainwright has increased its price target for Biodesix, Inc. (NASDAQ:BDSX) to $38 from $27, citing a stronger diagnostics multiple and confidence in the company's MRD testing strategy. Biodesix is advancing two ctDNA MRD programs, one tumor-informed with Bio-Rad and one tumor-naïve with Thermo Fisher, both moving towards MSK validation and partner lab rollout. This update follows the raised price target and highlights the progress in Biodesix's testing initiatives.
Thermo Fisher Scientific stock last trades at USD 677.36 on September 28, 2026
Thermo Fisher Scientific Inc. stock last traded at USD 677.36 on September 28, 2026, up 0.35 percent on the New York Stock Exchange. The company has scheduled the release of its third-quarter 2026 financial results for October 21, 2026, before market open, with a conference call to follow. This announcement was made by Thermo Fisher Scientific Investor Relations.
Can AbbVie’s Backing Help ADARx Win Over Biotech IPO Investors at a $1.74 Billion Valuation?
ADARx Pharmaceuticals is seeking to raise up to $371.9 million in a U.S. IPO, targeting a valuation of up to $1.74 billion, with significant backing from AbbVie Inc. AbbVie has agreed to invest up to $100 million in a concurrent private placement, giving it a 4.9% stake, and previously collaborated with ADARx with a $335 million payment. While ADARx has multiple programs, including a late-stage candidate onvuzosiran, the IPO's success hinges on investors' willingness to value experimental medicines given the selective biotech IPO market.
Thermo Fisher advances FTIR microscopy with faster, simplified molecular analysis
Thermo Fisher Scientific has launched the Nicolet RaptIR X FTIR Microscope, an advanced platform combining high-definition optical imaging with rapid infrared microspectroscopy. This new system aims to make chemical analysis of microscopic samples faster, simpler, and more accessible for laboratories across various fields. It offers high-speed data acquisition, high-resolution imaging, and user-friendly software, making it suitable for both experienced and new users while accommodating larger and more complex samples.
Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) announced it will release its third-quarter 2026 financial results before market open on Wednesday, October 21, 2026. The company will also host a conference call on the same day at 7:00 a.m. ET to discuss its financial performance and future expectations. The call will be webcast live on the company's website.
Press Release: Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026
Thermo Fisher Scientific will host its Q3 2026 earnings conference call on Wednesday, October 21, 2026. The call will discuss the company's financial results and provide an update on its business outlook. Investors and interested parties can access the webcast and presentation slides through the company's investor relations website.
Thermo Fisher Scientific and Evosep Enter Reseller Agreement for Evosep Eno
Thermo Fisher Scientific and Evosep have announced a reseller agreement for Evosep Eno, a separation platform designed for standardized proteomics workflows. This collaboration will allow Thermo Fisher Scientific to offer Evosep Eno, expanding access to robust, scalable, and reproducible proteomics solutions for researchers. The partnership aims to streamline access to next-generation LC-MS based proteomics and advance life science research through innovation and standardization.
Thermo Fisher Scientific and Evosep Enter Reseller Agreement for Evosep Eno
Thermo Fisher Scientific and Evosep have entered a reseller agreement for the Evosep Eno separation platform, aimed at expanding access to standardized, high-throughput proteomics workflows. This collaboration combines Thermo Fisher's global reach and mass spectrometry instruments with Evosep's innovative technology to provide robust, scalable, and reproducible proteomics solutions for research, drug discovery, and clinical applications. Customers will be able to purchase Evosep Eno directly through Thermo Fisher Scientific, streamlining access to this next-generation LC-MS based proteomics workflow.
Thermo Fisher Scientific stock at USD 675.00 on September 25, 2026
Thermo Fisher Scientific's stock closed at USD 675.00 on September 25, 2026, marking a 0.50% decrease from its previous close. The company recently launched a new CHO-K1 media and feed panel for cell culture, offering improved titer and viable cell density. Additionally, Thermo Fisher Scientific became a minority owner and founding partner in Mayo Clinic's new Precure venture, which aims to integrate various clinical data types for disease research.
Pfizer vs. Thermo Fisher: Which Healthcare Turnaround has More Upside?
This article compares the turnaround strategies and prospects of Pfizer (PFE) and Thermo Fisher Scientific (TMO) after difficult post-pandemic periods. Thermo Fisher demonstrates clearer operational momentum with strong organic growth and expanding margins, driven by an improving life-sciences market. Pfizer's turnaround is less advanced, relying on newer medicines and significant cost-cutting, but faces higher execution risk due to generic competition and the need for new product success.
Should Long Term Growth Targets Require Action From Charles River Labs Stock Investors?
Charles River Laboratories International recently presented long-term growth targets, including 5% to 7% organic revenue growth and low double-digit non-GAAP EPS growth, driven by AI and automation. These initiatives, particularly its rapid cell banking launch, are expected to generate significant savings and strengthen its Manufacturing Solutions mix. Investors are urged to assess the company's execution on these complex platforms and consider both optimistic and cautious analyst perspectives on future growth and potential downsides.
Is Charles River Laboratories Stock Outperforming the S&P 500?
Charles River Laboratories (CRL) stock has significantly outperformed the S&P 500 year-to-date and over the past year, driven by strong earnings and an optimistic future outlook. The company, a large-cap contract research organization, reported better-than-expected Q2 2026 results and raised its full-year EPS guidance, also projecting robust organic revenue growth and efficiency savings through 2030. Analysts maintain a "Strong Buy" rating for CRL.
What Is Castle Biosciences (CSTL) Signaling With Its New Atopic Dermatitis Study?
Castle Biosciences (CSTL) recently released new study data for its AdvanceAD-Tx test, a molecular diagnostic for atopic dermatitis, indicating strong patient interest and an unmet clinical need for personalized treatments. This study supports Castle Biosciences' strategy to expand its test menu into new disease areas beyond skin cancers, aiming to diversify revenue and tap into larger patient populations. However, the company still faces challenges regarding payer coverage and potential reimbursement risks for new tests.
Bio-Techne (TECH) Shareholders Approve the Merck KGaA Takeover and Reject the Pay Package
Bio-Techne (NASDAQ: TECH) shareholders have approved the company's acquisition by Merck KGaA for $73 per share, valuing the company at $11.3 billion. Although the antitrust waiting period in the U.S. has expired, the deal awaits further regulatory approvals and is expected to close in late 2026 or early 2027. Shareholders, however, rejected the executive compensation package, signaling their disapproval of the terms, although this vote is advisory and not binding.
Bio-Techne (TECH) Shareholders Approve the Merck KGaA Takeover and Reject the Pay Package
Bio-Techne (TECH) shareholders have approved the acquisition of the company by Merck KGaA for $73 a share, valuing the business at approximately $11.3 billion. Simultaneously, shareholders rejected the executive compensation proposal tied to the deal, signaling their disapproval of the pay arrangements. The deal is expected to close in late 2026 or early 2027, pending remaining regulatory approvals outside the U.S., with the focus now shifting from price to timing for investors.
Thermo Fisher Scientific's Building Blocks to 2028 Growth 'Fundamentally Sound,' Deutsche Bank Says
Deutsche Bank considers Thermo Fisher Scientific's growth strategy towards 2028 to be "fundamentally sound." The company's consistent execution and improvements in its end markets are key factors supporting this positive outlook. Access to the full article requires a premium subscription.
Advanced Biomed Inc. Common Stock (NYSE: ADVB) Stock Price, News & Analysis
This article provides a detailed financial overview and company profile for Advanced Biomed Inc. (NYSE: ADVB). It highlights the company's focus on microfluidic biochip technologies for oncology detection and treatment, lists key financial metrics and historical data, and compares it with peer companies in the Diagnostics & Research sector.
Sales fell 13% at Astrotech (ASTC), while its annual loss widened.
Astrotech Corporation reported a 13% decrease in fiscal year 2026 revenue, falling to $913,000 from $1.049 million in the prior year, primarily due to lower product sales. The company's net loss widened to $14.427 million from $13.850 million, and its gross margin dropped to 23.8% from 45.3%. Astrotech continues to pursue strategic initiatives, including potential lunar resource development and a possible sale of its 1st Detect subsidiary, while acknowledging the need for substantial additional capital to fund its long-term growth objectives.
Here's How Much a $1000 Investment in Thermo Fisher Scientific Made 10 Years Ago Would Be Worth Today
A $1000 investment in Thermo Fisher Scientific (TMO) made ten years ago would now be worth $4,302.87, representing a 330.29% gain, outperforming the S&P 500 and gold during the same period. The company's growth is attributed to strong customer activity, strategic acquisitions, new product development, and positive analyst forecasts, despite macroeconomic uncertainties.
